Enrollment Complete for Phase 2 Trial Testing Anti-fibrotic PLN-74809

Enrollment Complete for Phase 2 Trial Testing Anti-fibrotic PLN-74809

316050

Enrollment Complete for Phase 2 Trial Testing Anti-fibrotic PLN-74809

Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The company also announced that the U.S. Food and Drug Administration (FDA) has given the all-clear to conduct long-term dosing of PLN-74809 when given at doses up to…

You must be logged in to read/download the full post.